BioCryst Pharmaceuticals Inc. (BCRX)
NASDAQ · Healthcare
BioCryst Pharmaceuticals Inc. Operating Income 2009–2025
BioCryst Pharmaceuticals Inc. annual/quarterly operating income history and growth rate from 2009 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- BioCryst Pharmaceuticals Inc. operating income for the quarter ending March 31, 2026 was -701.6 M, a 3405.22% decrease year-over-year.
- BioCryst Pharmaceuticals Inc. operating income for the twelve months ending March 31, 2026 was -621.0 M, a 6137.38% increase year-over-year.
- BioCryst Pharmaceuticals Inc. annual operating income for 2025 was 341.0 M, a 13508.93% decrease from 2024.
- BioCryst Pharmaceuticals Inc. annual operating income for 2024 was -2.5 M, a 97.55% decrease from 2023.
- BioCryst Pharmaceuticals Inc. annual operating income for 2023 was -103.7 M, a 30.13% decrease from 2022.
- BioCryst Pharmaceuticals Inc. annual operating income for 2022 was -148.4 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BioCryst Pharmaceuticals Inc. Operating Income — FAQ
BioCryst Pharmaceuticals Inc. (BCRX) operating income over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
What is BioCryst Pharmaceuticals Inc.'s operating income?
BioCryst Pharmaceuticals Inc. (BCRX) reported operating income of $341M for fiscal 2025.
Where can I see BCRX's operating income history?
The chart and table above show BioCryst Pharmaceuticals Inc.'s operating income by year and by quarter, including the growth rate.